Citadel Advisors’s Dianthus Therapeutics DNTH Stock Holding History

Citadel Advisors’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.23M	Buy	43,400 +11,600	+36%	+$1.01M	﹤0.01%	5024
2026 Q1	$2.67M	Buy	31,800 +21,000	+194%	+$1.22M	﹤0.01%	5495
2025 Q4	$445K	Sell	10,800 -37,900	-78%	-$1.47M	﹤0.01%	9312
2025 Q3	$1.92M	Buy	+48,700	New	+$1.24M	﹤0.01%	6155
2025 Q2	–	Sell	-8,900	Closed	-$161K	–	13054
2025 Q1	$161K	Buy	8,900 +8,300	+1,383%	+$183K	﹤0.01%	10752
2024 Q4	$13.1K	Buy	600 +200	+50%	+$5.14K	﹤0.01%	13462
2024 Q3	$11K	Buy	+400	New	+$11.1K	﹤0.01%	13178
2023 Q2	–	Sell	-431	Closed	-$5.48K	–	14499
2023 Q1	$5.48K	Buy	431 +181	+72%	+$2K	﹤0.01%	13867
2022 Q4	$1.58K	Buy	+250	New	+$4.43K	﹤0.01%	14449
2022 Q1	–	Sell	-694	Closed	-$49K	–	13770
2021 Q4	$49K	Buy	+694	New	+$69.8K	﹤0.01%	13260

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Citadel Advisors's DNTH Position: Q2 2026 in Review

Citadel Advisors reduced its Dianthus Therapeutics (DNTH) stake by 39% in Q2 2026, selling an estimated $55.5M and leaving 974,911 shares worth $95M. The position accounts for 0.01% of the portfolio, ranked #1007.

Citadel Advisors first reported a position in DNTH in Q2 2018 and has held it in 27 quarters since. The position peaked at $135M in Q1 2026. 269 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Citadel Advisors held 974,911 shares of Dianthus Therapeutics worth $95M as of Q2 2026.
Citadel Advisors sold 635,572 Dianthus Therapeutics shares in Q2 2026, an estimated $55.5M.
Dianthus Therapeutics made up 0.01% of Citadel Advisors's portfolio in Q2 2026, its #1007 holding.
Citadel Advisors first reported a position in Dianthus Therapeutics in Q2 2018 and has held it in 27 quarters since.
Citadel Advisors's Dianthus Therapeutics position peaked at $135M in Q1 2026.
269 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.